William Blair Starts Portola Pharmaceuticals (PTLA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Morgan Stanley Starts Portola Pharmaceuticals (PTLA) at Overweight
June 17, 2013 7:26 AM EDTMorgan Stanley initiates coverage on Portola Pharmaceuticals (NASDAQ: PTLA) with a Overweight. PT $32.00.
For an analyst ratings summary and ratings history on Portola Pharmaceuticals click here. For more ratings news on Portola Pharmaceuticals click here.
Shares of Portola Pharmaceuticals closed at $20.05 yesterday, with a 52 week range of $14.75-$29.79.... More
